Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis

@inproceedings{Kalincik2013PersistenceOT,
  title={Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis},
  author={Tomas Kalincik and Timothy D Spelman and Maria Trojano and Pierre Duquette and Guillermo Izquierdo and Pierre Grammond and Alessandra Lugaresi and Raymond M. M. Hupperts and Edgardo Cristiano and Vincent van Pesch and François Grand’Maison and Daniele La Spitaleri and Maria Edite Rio and Sholmo Flechter and Celia Oreja-Guevara and Giorgio Giuliani and Aldo Savino and Maria Pia Amato and Thor Petersen and Ricardo Fern{\'a}ndez-Bola{\~n}os and Roberto Bergamaschi and Gerardo Iuliano and Cavit Boz and Jeannette S. Lechner-Scott and Norma Deri and Orla M Gray and Freek Verheul and Marcela P. Fiol and Michael Barnett and E. T. H. van Munster and Vetere Santiago and Fraser Moore and Mark Slee and Mar{\'i}a Laura Saladino and Raed Alroughani and Cameron Shaw and Kriszti{\'a}n K{\'a}sa and Tatjana Petkovska-Boskova and Leontien den Braber-Moerland and J. Chapman and Eli Skromne and Joseph Herbert and Dieter Poehlau and Merrilee Needham and Elizabeth Alejandra Bacile Bacile and Walter Oleschko Arruda and Mark Paine and Bhim Singhal and Steve Vucic and Jose Antonio Cabrera-Gomez and Helmut Butzkueven and {\'E}laine Roger and Pierre Despault and Mark Marriott and Anneke van der Walt and J. V. King and Trevor J. Kilpatrick and Katherine Buzzard and Vilija G Jokubaitis and Jill Byron and Lisa Morgan and Olga Skibina and Jodi Haartsen and Giovanna De Luca and Valeria di Tommaso and Daniela Travaglini and Erika Pietrolongo and Maria di Ioia and Deborah Farina and Luca Mancinelli and Damiano Paolicelli and Pietro Iaffaldano and Juan Ignacio Rojas and Liliana Patrucco and Etienne Roullet and Jorge Correale and C{\'e}lica Ysrraelit and Cartechini Elisabetta and Eugenio Pucci and David Williams and Lisa Dark and Vahid Shaygannejad and Cees Zwanikken and Norbert R Vella and C Sirbu},
  booktitle={PloS one},
  year={2013}
}
OBJECTIVES To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. METHODS Treatment discontinuations were evaluated in all… CONTINUE READING